Showing 131-140 of 5352 results for "".
DWTV Extra: Image-Guided SRT Consensus
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-image-guided-srt-consensus/35744/Jacob Scott, MD, chairman of the Dermatology Association of Radiation Therapy (DART), discusses an expert panel's recommendations on the role of image-guided superficial radiation therapy in the treatment of non melanoma skin cancer, which were published in an article titled "The Role of Image-GuideThe Evidence for Slow- and Fast-growing Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/1109_06-php/22058/Recent findings support the existence of slow-growing melanomas, offering a possible explanation for anomalies in melanoma incidence reporting.The State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andStudy Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeScience of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oDr. Battle on Skin of Color Update and Minimizing, Treating Complications from Energy-Based Devices
https://practicaldermatology.com/topics/skin-of-color/dr-battle-skin-color-update-and-minimizing-treating-complications-energy-based-devices/28655/Eliot Battle, MD, discusses the growth of Skin of Color Update, minimizing and treating complications when treating patients of skin of color, and integrating energy-based devices into your practice.DermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliEffective Patient Consultations: Keys to Success
https://practicaldermatology.com/topics/practice-management/effective-patient-consultations-keys-to-success/20122/So much depends on the patient consultation, and its key that all members of the practice staff are attentive to the needs of the patient and the practice. Amy Lewis, MD and Mark Rubin, MD weigh in on strategies for effective patient interactions.Embracing AI
https://practicaldermatology.com/topics/practice-management/embracing-ai/20080/Artificial intelligence is something dermatologists should be embracing as augmented intelligence. Anthony Rossi, MD says this intelligence will allow us to better diagnose, assess, and treat patients with everything from acne to melanoma.